MedTrace Logo

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

NCT01465659 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-08-05

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the side effects and best dose of temozolomide and pazopanib hydrochloride when given together and to see how well they work in treating patients with advanced pancreatic neuroendocrine tumors (PNET) that cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Giving temozolomide together with pazopanib hydrochloride may be an effective treatment for patients with PNET.

Conditions

  • Pancreatic Alpha Cell Carcinoma
  • Pancreatic Beta Islet Cell Carcinoma
  • Pancreatic Delta Cell Carcinoma
  • Pancreatic G-cell Carcinoma
  • Recurrent Islet Cell Carcinoma

Interventions

DRUG

temozolomide

Given PO

DRUG

pazopanib hydrochloride

Given PO

Sponsors & Collaborators

Principal Investigators

  • Halla Nimeiri · Northwestern University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-12
Primary Completion
2018-07-30
Completion
2021-01-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01465659 on ClinicalTrials.gov